Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia

In non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations, exon 20 in-frame insertions (Exon20ins) are the third most common type of mutations, and is estimated to occur in 4  %–12 % of patients [1,2]. Previous studies have reported poor outcomes in NSCLC patients with EGFR Exon20ins treated with tyrosine-kinase inhibitors approved for NSCLC with common EGFR mutations (classical TKIs), suggesting that the development of targeted therapy for NSCLC patients harboring EGFR Exon20ins is an unmet need [3,4,5,6].

Source: Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, Terufumi Kato, Hiroshi Yokouchi, Naoki Furuya, Ryota Kanemaru, Ryo Toyozawa, Akihiro Nishiyama, Kadoaki Ohashi, Shingo Miyamoto, Kazumi Nishino, Atsushi Nakamura, Eiji Iwama, Seiji Niho, Hajime Oi, Tetsu Tags: Research Paper Source Type: research